These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 20085477

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Health and economic implications of HPV vaccination in the United States.
    Kim JJ, Goldie SJ.
    N Engl J Med; 2008 Aug 21; 359(8):821-32. PubMed ID: 18716299
    [Abstract] [Full Text] [Related]

  • 23. The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan.
    Yamabe K, Singhal PK, Abe M, Dasbach EJ, Elbasha EH.
    Value Health Reg Issues; 2013 May 21; 2(1):92-97. PubMed ID: 29702859
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
    Östensson E, Fröberg M, Leval A, Hellström AC, Bäcklund M, Zethraeus N, Andersson S.
    PLoS One; 2015 May 21; 10(9):e0139062. PubMed ID: 26398189
    [Abstract] [Full Text] [Related]

  • 27. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA, Gow J, Alam K, Keramat SA, Hossain MG, Sultana M, Sarker AR, Islam SMS.
    Vaccine; 2020 Jan 10; 38(2):165-172. PubMed ID: 31668820
    [Abstract] [Full Text] [Related]

  • 30. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.
    Vaccine; 2011 Oct 26; 29(46):8443-50. PubMed ID: 21816193
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
    Kind AB, Pavelyev A, Kothari S, El Mouaddin N, Schmidt A, Morais E, Guggisberg P, Lienert F.
    BMC Public Health; 2020 May 12; 20(1):671. PubMed ID: 32398057
    [Abstract] [Full Text] [Related]

  • 33. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
    Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.
    Vaccine; 2013 Aug 20; 31(37):3899-905. PubMed ID: 23820080
    [Abstract] [Full Text] [Related]

  • 34. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
    Haeussler K, Marcellusi A, Mennini FS, Favato G, Picardo M, Garganese G, Bononi M, Costa S, Scambia G, Zweifel P, Capone A, Baio G.
    Value Health; 2015 Dec 20; 18(8):956-68. PubMed ID: 26686779
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.
    Vaccine; 2013 Aug 20; 31(37):3863-71. PubMed ID: 23830974
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand.
    Termrungruanglert W, Khemapech N, Vasuratna A, Havanond P, Deebukkham P, Kulkarni AS, Pavelyev A.
    PLoS One; 2021 Aug 20; 16(2):e0245894. PubMed ID: 33571186
    [Abstract] [Full Text] [Related]

  • 39. Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.
    Michaeli DT, Stoycheva S, Marcus SM, Zhang W, Michaeli JC, Michaeli T.
    Clin Drug Investig; 2022 Apr 20; 42(4):333-343. PubMed ID: 35294726
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.
    Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM.
    Vaccine; 2007 Dec 21; 26(1):128-39. PubMed ID: 18055075
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.